Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling

BACKGROUND: Darunavir 800 mg once (q24h) or 600 mg twice (q12h) daily combined with low-dose ritonavir is used to treat HIV-positive pregnant women. Decreased total darunavir exposure (17%–50%) has been reported during pregnancy, but limited data on unbound exposure are available. OBJECTIVES: To eva...

詳細記述

保存先:
書誌詳細
出版年:J Antimicrob Chemother
主要な著者: Schalkwijk, Stein, ter Heine, Rob, Colbers, Angela, Capparelli, Edmund, Best, Brookie M, Cressey, Tim R, Greupink, Rick, Russel, Frans G M, Moltó, José, Mirochnick, Mark, Karlsson, Mats O, Burger, David M
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Original Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6477987/
https://ncbi.nlm.nih.gov/pubmed/30715324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dky567
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料